Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Buclin

Showing results (11-20 of 251) with videos related to

Pageof 26
Sort By:
Current Opinion in Neurology|September 3, 2013
Toxic and drug-induced peripheral neuropathies: updates on causes, mechanisms and managementManuel Diezi, Thierry Buclin, Thierry Kuntzer
Therapeutic Drug Monitoring|November 23, 2013
Response to Diaz and de Leon "the mathematics of drug dose individualization should be built with random effects linear models"Nicholas H G Holford, Thierry Buclin
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|January 25, 2008
Misleading tacrolimus concentration value in blood taken from a catheter used for tacrolimus administrationEric Grouzmann, Thierry Buclin, Jérôme Biollaz
Lancet (London, England)|January 30, 2007
GliptinsEric Grouzmann, Thierry Buclin, Jérôme Biollaz
Journal of Clinical Pharmacology|October 26, 2020
Parametric Approaches in Population PharmacokineticsMonia Guidi, Chantal Csajka, Thierry Buclin
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|March 9, 2017
Cascaded PID controller for anaesthesia deliveryAlena Simalatsar, Monia Guidi, Thierry Buclin
Revue Medicale Suisse|March 16, 2007
[Pharmacovigilance and teratovigilance]Françoise Livio, Thierry Buclin, Jérôme Biollaz
Clinical Pharmacology and Therapeutics|May 21, 2005
The importance of assessing the dose actually administered in pharmacokinetic trialsThierry Buclin, Nancy Perrottet, Jerome Biollaz
Hypertension (Dallas, Tex. : 1979)|July 8, 2009
Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedemaEric Grouzmann, Françoise Livio, Thierry Buclin
Revue Medicale Suisse|March 4, 2010
[Angioedema during ACE and DPP-4 inhibition]Bernard Waeber, Thierry Buclin, Eric Grouzmann
Pageof 26

Showing results (11-20 of 251) with videos related to

Sort By:
Pageof 26
Current Opinion in Neurology|September 3, 2013
Toxic and drug-induced peripheral neuropathies: updates on causes, mechanisms and managementManuel Diezi, Thierry Buclin, Thierry Kuntzer
Therapeutic Drug Monitoring|November 23, 2013
Response to Diaz and de Leon "the mathematics of drug dose individualization should be built with random effects linear models"Nicholas H G Holford, Thierry Buclin
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|January 25, 2008
Misleading tacrolimus concentration value in blood taken from a catheter used for tacrolimus administrationEric Grouzmann, Thierry Buclin, Jérôme Biollaz
Lancet (London, England)|January 30, 2007
GliptinsEric Grouzmann, Thierry Buclin, Jérôme Biollaz
Journal of Clinical Pharmacology|October 26, 2020
Parametric Approaches in Population PharmacokineticsMonia Guidi, Chantal Csajka, Thierry Buclin
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|March 9, 2017
Cascaded PID controller for anaesthesia deliveryAlena Simalatsar, Monia Guidi, Thierry Buclin
Revue Medicale Suisse|March 16, 2007
[Pharmacovigilance and teratovigilance]Françoise Livio, Thierry Buclin, Jérôme Biollaz
Clinical Pharmacology and Therapeutics|May 21, 2005
The importance of assessing the dose actually administered in pharmacokinetic trialsThierry Buclin, Nancy Perrottet, Jerome Biollaz
Hypertension (Dallas, Tex. : 1979)|July 8, 2009
Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedemaEric Grouzmann, Françoise Livio, Thierry Buclin
Revue Medicale Suisse|March 4, 2010
[Angioedema during ACE and DPP-4 inhibition]Bernard Waeber, Thierry Buclin, Eric Grouzmann
Pageof 26